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Abstract
Purpose: We present the outcomes of microwave ablation (MWA) of renal cell carcinoma (RCC) with and without 
pyeloperfusion.
Material and methods: A retrospective review of patients’ records was undertaken to identify patients with RCC, who 
were treated with MWA with and without adjunctive pyeloperfusion. The distance between the tumour and ureter as 
well as the tumour size were measured on axial imaging. Pyeloperfusion was performed in nine patients in this series 
after placement of a ureteral stent and instilment of diluted contrast into the ureter. MWAs of the tumours were per-
formed under computed tomography (CT) guidance. Hydrodissection was performed to displace at-risk organs. Crea-
tinine was measured as renal function index after and before the procedure. A CT scan was performed at the end of 
the procedure and also after one, three, and six months, to identify the presence of residual disease and complications.
Results: Eighteen biopsies of proven RCC were treated with 20 sessions of MWA. The average follow-up time for this 
study was 180 days. The average distance between the ureter and the tumour in axial CT view was 20.8 (± 2.9) mm. 
Primary efficacy was achieved in 88% of pyeloperfused patients and in 100% of the non-pyeloperfused patients. Two 
pyeloperfused patients required secondary procedure, and full secondary efficacy was achieved for both. There was 
only one grade 2 urological complication, which occurred in a patient who underwent pyeloperfusion. Creatinine 
was not significantly different after the procedure in this study (p-value 0.4). 
Conclusion: In this study MWAs of RCCs were successfully performed using pyeloperfusion as a protective measure 
against thermal injury to the ureter. 
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Introduction
Advances in imaging modalities and diagnostic techniques 
have led to an increase in the detection and diagnosis of 
renal cell carcinoma (RCC) [1]. While partial nephrecto-
my is considered the gold standard treatment for RCCs, 
ablative therapies such as radiofrequency ablation (RFA), 
cryoablation (CA), and microwave ablation (MWA) are 
alternatives to nephrectomy in selected patients for whom 
surgery may not be an option [2]. Of the three current-
ly available thermal ablative options RFA and CA are the 
most extensively investigated, and several studies have 
demonstrated similar clinical efficacies for RFA and CA 
for the management of small renal cell tumours [3,4].
MWA is the latest technique and may offer the bene-
fits of faster ablation time and higher temperatures, which 
could translate to successful treatment of larger tumours 
[5,6]. Emerging studies have demonstrated the effective-
ness of MWA in the treatment of T1b RCCs, with high 
technical success [7,8].
Non-target organ injury is a dreaded complication for 
any thermal ablation technique. This is especially relevant 
Katayoun Samadi, Ronald Arellano  
e448 © Pol J Radiol 2019; 84: e447-e452
for thermal ablation adjacent to the ureter, where ureteral 
injury can result in devastating consequences of urino-
ma, ureteral stricture, and hydronephrosis. To mitigate 
this risk, several authors have described the technique 
of ureteral cooling with pyeloperfusion as an adjunctive 
technique during RFA for RCC [9,10]. 
In contrast to RFA, which generates frictional heat via 
ionic agitation, MWA achieves tumouricidal temperatures 
through agitation of water molecules. As a result, MWA 
could theoretically increase the risk of thermal injury dur-
ing MWA for RCC in proximity to the ureter. The purpose 
of this study was to present the preliminary outcomes 
of computed tomography (CT)-guided MWA with ad-
junctive pyeloperfusion in the treatment of centrally lo-
cated RCCs. 
Material and methods
Patients
The Institutional Review Board approved this Health 
Insurance Portability and Accountability Act-compliant 
retrospective analysis. An institutional database was re-
viewed to retrospectively identify patients with biopsy- 
proven RCC treated with MWA between January 2016 
and September 2017. The patients were then stratified into 
two cohorts: one cohort consisted of patients with RCC, 
who were treated with adjunctive pyeloperfusion; the 
second cohort consisted of patients with RCC, who were 
matched based on tumour characteristics with the former 
group, and who were treated without pyeloperfusion. Se-
lection of patients for either group was based on the in-
terventional radiologist’s clinical judgement, and the size 
and location of the tumour. Technical success was defined 
as completion of the planned procedures. Treatment out-
comes were assessing by contrast material-enhanced CT 
or magnetic resonance imaging (MRI) at one month post-
MWA and then at six-month intervals thereafter. Collect-
ed data were evaluated for technical success, primary effi-
cacy, secondary efficacy, renal function and duration, and 
number of procedures. The choice of pyeloperfusion was 
made on a case-by-case basis by an interventional radiol-
ogist considering centrally located tumours or tumours 
arising from the medial lower pole of the kidney and the 
risk of thermal injury to the ureter. The distance between 
the tumour and ureter and tumour size were measured on 
axial imaging. Locations of the tumours were categorised 
as exophytic, parenchymal, and mixed. Pre- and post-se-
rum creatinine levels were measured. Patient and tumour 
characteristics are presented in Table 1.
Procedure
All ablations were performed with curative intent. The 
diagnosis of RCC was previously established by percuta-
neous biopsy. All ablations were performed with gener-
al anaesthesia or with intravenous procedural sedation. 
Computed tomography guidance (16-slice Lightspeed; GE 
Medical Systems, Madison, Wisconsin) was used for all 
procedures. 
When critical non-target organs were adjacent to the 
targeted tumours, hydrodissection was performed by in-
stillation of contrast-laced normal saline (10 cc Isovue 
mixed with 500 cc 0.9% normal saline) to displace struc-
tures away from the kidney (Figure 1). 
Pyeloperfusion was performed in nine patients whose 
tumours were within 2 cm of the proximal ureter. Im-
mediately prior to the procedure, a urologist placed a 5F 
open-ended ureteral stent (Pollack Open-End Flexi-Tip 
Ureteral Catheter; Cook Urological, Inc., Spencer, Indi-
ana) into the ipsilateral ureter (Figure 2) with the dis-
tal end of the stent placed in the ipsilateral renal pelvis. 
The proximal end was externalised through the meatus 
and attached to a 1000 cc bag of 0.9% normal saline and 
drip infused at approximately 1 drop/sec.
At the end of the treatment a CT was performed to 
assess immediate complications. And immediately after 
the procedure the stent was removed. Surveillance imag-
ing was done with CT and MRI with intervals of 1, 6, and 
12 months and then annually to determine the presence of 
residual disease or collecting system injury. Complications 
were classified with the Clavien-Dindo system [11]. Re-
peat ablation was done if residual disease or new tumour 
was detected in surveillance imaging. 
Table 1. Patient and tumour characteristics for pyeloperfusion and non- 
pyeloperfusion groups
Characteristic Pyeloperfused 
group
Non-
pyeloperfused 
group
p-value
Number of patients 9 9
Age mean (± SD) 69.78 (± 10.61) 69.22 (± 10.52) 0.91
Gender (%) 
Male 8/9 (89) 7/9 (77) 0.50
Female 1/9 (11) 2/9 (22)
Size of tumour (mm) 32.78 (± 12.63) 29.22 (± 8.05) 0.41
Tumour polarity (%)
Upper 1/9 (11) 2/9 (22) 0.33
Interpolar 2/9 (22) 0/9 (0)
Medial lower 6/9(66) 7/9 (77)
Tumour location (%)
Parenchymal 4/9 (44) 4/9 (44) 0.11
Exophytic 2/9 (22) 5/9 (55)
Mixed 3/9 (33) 0/9 (0)
Distance to ureter 
(± SD)
18.44 (± 12.63) 23.22 (± 12.71) 0.43
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Assessment of treatment response
Assessment of the procedure was based on previously 
reported criteria [10]. Technical success was defined as 
successful completion of the planned ablation. Residu-
al tumour was defined as persistent tumoural enhance-
ment on CT or MRI on the first follow-up scan after the 
procedure. Primary efficacy and secondary efficacy were 
defined as percentage of tumours eradicated in first and 
second ablation sessions, respectively.
Data collection and analysis
Clinical and pathological features of the tumours were 
recorded and analysed retrospectively. Data for continu-
ous variables were expressed as absolute numbers (mean 
± SD). Paired t-test was used to compare means of con-
tinuous variables and Fisher exact test for comparison of 
percentage differences between different groups. A p-val-
ue < 0.05 was considered statically significant. All statisti-
cal analyses were performed by using statistical software 
(SPSS 16.0; SPSS, Chicago, IL).
Results
This was an IRB approved study with waiver of patients 
consent (protocol number is 2018P001233). Eighteen 
biopsy-proven RCCs in 18 patients were treated with 
A
B
C
Figure 1. A) Pre-procedure computed tomography after placing a ureteral stent 
(arrow), demonstrating proximity of the ureter to the tumour (dashed circle). 
B) The ureter (narrow arrow) is displaced from the surface of the tumour 
(dashed circle) by instillation of diluted contrast (thick arrow). C) Micro wave 
ablation of the tumour after pyeloperfusion (blue arrowhead) and hydrodis-
section (arrows) of the ureter; curved arrow shows ablation antenna 
Figure 2. A) White arrow indicates central tumour; asterisk indicates renal 
pelvis. B) White arrow indicates stent for pyeloperfusion. C) White needle 
indicates microwave ablation antenna
A
B
C
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19 sessions of MWA. The mean age of the patients was 
69 ± 2.4 years. The study patients were predominant-
ly male (84%). The tumour locations were classified as 
parenchymal (n = 8, 44%), exophytic (n = 7, 38%), and 
mixed (n = 3, 16%). Mean tumour diameter was 31 mm 
(± 2.2 mm). The average distance between ureter and the 
tumours in the pyeloperfused versus the non-pyelop-
erfused groups was 18.44 and 23.22 (p = 0.43), respec-
tively, as summarised in Table 1. Hydrodissection was 
performed for two patients to displace the kidney from 
the psoas muscle and to displace the colon away from the 
kidney. The tumour polarity of this study is composed of 
13 (72%) medial lower tumours, three (16%) upper, and 
two (11%) interpolar tumours. The mean procedure time 
was 118 minutes. The average follow-up period was 180 
days. Nine of 18 (50%) patients had more than six months 
of follow-up. Mean pre- and post-creatinine values for 
the entire study were 1.80 and 1.99 mg/dl, respectively 
(p = 0.4). The treatment outcomes for pyeloperfused and 
non-pyeloperfused groups are presented in Table 2.
Technical success was achieved for all patients. One 
pyeloperfused patient had residual disease on the one-
month follow-up, which was treated by repeat ablation. 
There were two grade 1 complications, including one 
small retroperitoneal haematoma and one small haemat-
oma with concurrent pneumothorax. Both of these minor 
complications were treated conservatively. 
There was one grade 2 complication, which consisted 
of ureteral stricture in a patient treated with pyeloperfu-
Table 2. Comparison of outcomes between pyeloperfusion and non- 
pyeloperfusion groups
Efficacy measure Pyeloperfused
group
Non-
pyeloperfused 
group (%)
p-value
Residual disease (%) 1/9 (11%) 0/9 (0) 1.00
Primary efficacy (%) 8/9 (88) 9/9 (100) 1.00
Secondary efficacy 2/2 (100) 0
Creatinine (%)* 
Before 1.44 (± 0.49) 2.16 (± 1.54)
After 1.5 (± 0.48) 2.15 (± 1.54)
Duration of the 
procedure (± SD)**
144 (± 35.34) 95.5 (± 34.04) 0.004
Number of ablative 
sessions
10 9
Overall 
complication (%)
2/9 (22) 1/9 (11) 1.00
*There was no significant difference in serum creatinine pre- and post-ablation for either group 
after and before the procedure in the pyeloperfused group or in the non-pyeloperfused group
**Significant difference was because of the time required for stenting for pyeloperfusion
Figure 3. A) Axial unenhanced computed tomography (CT) scan of the ab-
domen at the time of ablation. Patient is in the left lateral decubitus posi-
tion. White arrow indicates stent in the left ureter. White asterisk indicates 
renal cell carcinoma. B) Axial unenhanced CT scan of the abdomen at the 
time of ablation. Patient is in the left lateral decubitus position. White thin 
arrow indicates stent in the left ureter. White thick arrow indicates micro-
wave ablation antenna. At the conclusion of the procedure, it was noted 
that the tubing connecting the bag of 0.9% normal saline to the ureteral 
stent became disconnected. As a result, it was likely that there was effective 
pyeloperfusion during treatment. C) Fluoroscopic images taken at the time 
of left retrograde pyelogram that demonstrate proximal ureteral stricture 
(black arrow) 
A B
C
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Table 3. Ablation outcomes based on tumour characteristics
Characteristic Number (%) Primary efficacy p-value
Size
≥ 3 mm 11/18 (61) 10/11 (90) 1.00
< 3 mm 7/18 (38) 7/7 (100)
Location
Exophytic 8/18 (44) 7/8 (87) 0.44
Parenchymal 7/18 (38) 7/7 (100)
Mixed 3/18 (16) 3/3 (100)
Polarity 
Mid pole 2/18 (11) 2/2 (100) 1.00
Upper 3/18 (16) 3/3 (100)
Lower 13/18 (72) 12/13 (92)
Distance to ureter 
≥ 20 mm 10/18 (55) 10/10 (100) 0.44
< 20 mm 8/18 (44) 7/8 (87)
Tumoural side
Left 13/18 (72) 12/13 (92) 1.00
Right 5/18 (27) 5/5 (100)
sion. The tumour was 55 mm in size and was located with-
in 10 mm of the ureter (Figure 3). At the conclusion of the 
procedure, the ureteral stent was found to be disconnected 
from the 0.9% normal saline used for the drip infusion. 
Thus, we assume that, despite adequate positioning of 
the ureteral stent, pyeloperfusion was effectively not per-
formed during the procedure. The patient ended up having 
a urological surgery to resolve the stricture.
Technical success was 100% for this study. Tumour 
location, polarity, and size were not identified as inde-
pendently predictive of primary success in MWA (Table 3). 
Discussion
Microwave ablation is a thermal ablative method that is 
used to treat liver and renal tumours. Its mechanism of ac-
tion is based on electromagnetic waves that produce heat 
by agitation of water molecules, which leads to coagula-
tion necrosis of the tissue and has a similar effectiveness 
profile compared to radiofrequency ablation [6,12,13]. 
Because water is the main component of urine, there 
is a theoretically risk that MWA with pyeloperfusion may 
expose the ureter to increased risk of thermal injury. 
The results of this study show that with pyeloperfusion, 
MWA can be used to safely and effectively treat tumours 
near the renal pelvis and proximal ureter. The one case in 
our series of ureteral stricture that developed after MWA 
of a T1b tumour was probably the result of thermal injury 
to the ureter in the setting of pyeloperfusion failure due 
to a technical malfunction of the pyeloperfusion appa-
ratus. 
Location of the tumour is an important factor in the 
prediction of success and complication rate. Gervais et al. 
[14] showed that 25% of patients who underwent RF ab-
lation for tumours within 1 cm of the ureter had ureteral 
stricture, whereas stricture resulted in 10% of the tumours 
within 1-2 cm of the ureter. 
Pyeloperfusion is an adjunctive manoeuvre that has 
been shown to protect the ureter from thermal injury 
during radiofrequency ablation. Dai et al. [10] assessed 
the efficacy of RF ablation with pyeloperfusion in the 
management of central renal tumours and showed that 
compared to previous works [14,15] the overall efficacy of 
the technique was improved after adding pyeloperfusion 
as an adjunct technique. There are two available studies 
demonstrating the clinical efficacy and safety of pyelop-
erfusion with RF ablation [9,10]. While pyeloperfusion 
with RFA has demonstrated safety, there are currently no 
reports of effectiveness of pyeloperfusion with MWA to 
treat RCC near the ureter or renal pelvis. Technical suc-
cess was achieved for all patients in our study groups. 
Primary efficacy was achieved for 89% of pyeloperfused 
patients, which is higher compared to the results on RF 
and pyeloperfusion [9,10], and the overall success rate of 
the study was 94%, which is comparable with other in-
itial report on MWA [8]. Schmit et al. [16] showed that 
the primary effectiveness of radiofrequency ablation is 
limited to exophytic and small (< 3) tumours; however, we 
found no relation between ablation outcome and tumour 
complexity factors, including size, location, and polarity 
independently. 
There were only two grade 1 (Clavien-Dindo 1) com-
plications and one grade 2 complication, which was most 
likely due to pyeloperfusion malfunction. The complica-
tion rate in our study was similar to previous reports that 
assessed the efficacy of MWA in the treatment of renal 
tumours with larger groups of patients [7,8]. Cantwell 
et al. [9] reported 19 RF ablations with adjunctive pyelop-
erfusion without any ureteral stricture. In our study the 
only case of ureteral stricture was a patient with malfunc-
tioned pyeloperfusion. Dong et al. [17] demonstrated in 
their study that haematoma is more prevalent in exophytic 
tumours, while urinary tract complications occur mainly 
in endophytic tumours. One study by Castle et al. [18] re-
ported a 20% intraoperative and 40% postoperative com-
plication rate in MWA of RCCs, which is probably due to 
the involvement of the urinary tract in half of the patients, 
However, the efficacy of pyeloperfusion in protecting the 
urinary tract was not evaluated in this study. 
Similarly to the earlier study by Dong et al. [17], we 
found no significant different between renal function af-
ter and before ablation. In another study Wah et al. [19] 
showed that there was 3.1% worsening of renal function 
after performing RF for lower lobe renal tumours.
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Limitations
This study has several limitations. It is a non-ran-
domised retrospective analysis of a small cohort of pa-
tients. While the results are encouraging, the small pa-
tient population limits the generalisability of the results. 
A larger cohort would be helpful to evaluate the validity 
of our results. The study is also limited by a short over-
all follow-up period. This is due, in part, to the relatively 
short time that MWA has been used at our institution. We 
hope to report long-term results as they become available. 
The results of this study suggest that microwave ablation 
of centrally located tumours with pyeloperfusion is safe 
and effective and should be considered as an alternative 
thermal ablation modality to RFA and cryoablation for 
the treatment of RCC. 
Conclusions
Hydrodissection is a useful adjunctive technique for MWA 
of RCCs to keep adjacent structures from untargeted ther-
mal injury. Pyeloperfusion is a technique to protect the ure-
ter from thermal injury during MWA of lower renal pole 
tumours. MWA is a safe and effective treatment for RCC.
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